Qilu Pharmaceutical's Cisplatin Fully Distributed in U.S., Renewed Shortage Looms

Sep 20, 2023 12:10 CST Updated 12:10

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

On September 18, the FDA website showed a shortage of cisplatin. The chemotherapy drug cisplatin provided by Qilu Pharmaceutical Co., Ltd. has been fully distributed, while several other companies are also facing shortages.

In July, FDAFacing Severe Shortage of Anticancer Drug Cisplatin Due to Intas Factory Closure,Urgently import cisplatin from Qilu Pharmaceutical Co., Ltd., distributed in the U.S. by Apotex.

Qilu Pharmaceutical Co., Ltd. General Manager Zhang Hanchang stated in July: The first batch of cisplatin, totaling more than 20,000 vials, was shipped on May 31 and was quickly snapped up by medical institutions after entering the U.S. market. About 20 days later, the U.S. FDA placed a second order for nearly 50,000 vials, which were also immediately reserved by medical institutions. Currently, Qilu Pharmaceutical is in communication with the U.S. FDA regarding a third order, totaling 10 batches.

According to the White House, the supply of cisplatin in the United States has almost returned to pre-shortage levels.100%. However, the supply of cisplatin from Qilu Pharmaceutical has been exhausted, which may further shorten the supply.

From this MarchMonthStarting, the United StatesCisplatin has been in short supply.StatusState.

Teva Pharmaceuticals reported a shortage of its cisplatin injection due to increased customer demand and is currently "allocating the existing limited supply."

Previous Recommendations

Full Review of Hengrui Medicine's Biologics Pipeline

Overview of Zhongsheng Pharmaceutical Enterprises

Shiyao Group Biopharmaceutical Technology Platform and Pipeline Review

Summary of Other Effects of GLP-1 Beyond Hypoglycemic and Weight Loss

Click "PharmResearch Network" below to follow more exciting content.